A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma.
Morris
D L
DL
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D009367:Neoplasm Staging; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy; D013004:Somatostatin / Q000008:administration & dosage / Q000627:therapeutic use; D015996:Survival Rate
D018931:Antineoplastic Agents, Hormonal; D006727:Hormone Antagonists; D013004:Somatostatin; D015282:Octreotide